drugset / Trial / NCT01529593

Temsirolimus in Combination With Metformin in Patients With Advanced Cancers

NCT01529593

Phase 1 Terminated 34 enrolled M.D. Anderson Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and best dose of temsirolimus and metformin hydrochloride in treating patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced or metastatic). Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Metformin hydrochloride is a drug used to treat diabetes that may also prevent or slow the growth of cancers. Giving temsirolimus and metformin hydrochloride together may kill more tumor cells.

Timeline

Start
2012-03-26
Primary completion
2025-03-14
Completion
2025-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 500 mg Oral
Subject Temsirolimus Small molecule 25 mg Intravenous